

# Sergio A Giralt

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8111961/publications.pdf>

Version: 2024-02-01

277  
papers

15,532  
citations

34016

52  
h-index

20307

116  
g-index

280  
all docs

280  
docs citations

280  
times ranked

15164  
citing authors

#	ARTICLE	IF	CITATIONS
1	Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia. <i>Science Translational Medicine</i> , 2014, 6, 224ra25.	5.8	2,069
2	Defining the Intensity of Conditioning Regimens: Working Definitions. <i>Biology of Blood and Marrow Transplantation</i> , 2009, 15, 1628-1633.	2.0	1,419
3	The effects of intestinal tract bacterial diversity on mortality following allogeneic hematopoietic stem cell transplantation. <i>Blood</i> , 2014, 124, 1174-1182.	0.6	711
4	Intestinal <i>Blautia</i> Is Associated with Reduced Death from Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1373-1383.	2.0	619
5	Hepatic Venous Occlusive Disease following Stem Cell Transplantation: Incidence, Clinical Course, and Outcome. <i>Biology of Blood and Marrow Transplantation</i> , 2010, 16, 157-168.	2.0	509
6	Microbiota as Predictor of Mortality in Allogeneic Hematopoietic-Cell Transplantation. <i>New England Journal of Medicine</i> , 2020, 382, 822-834.	13.9	435
7	Indications for Autologous and Allogeneic Hematopoietic Cell Transplantation: Guidelines from the American Society for Blood and Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1863-1869.	2.0	342
8	Hematopoietic cell transplantation-specific comorbidity index as an outcome predictor for patients with acute myeloid leukemia in first remission: combined FHCRC and MDACC experiences. <i>Blood</i> , 2007, 110, 4606-4613.	0.6	292
9	International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders. <i>Lancet Oncology</i> , The, 2019, 20, e302-e312.	5.1	290
10	Reconstitution of the gut microbiota of antibiotic-treated patients by autologous fecal microbiota transplant. <i>Science Translational Medicine</i> , 2018, 10, .	5.8	258
11	Phase 3 trial of defibrotide for the treatment of severe veno-occlusive disease and multi-organ failure. <i>Blood</i> , 2016, 127, 1656-1665.	0.6	255
12	Lactose drives <i>Enterococcus</i> expansion to promote graft-versus-host disease. <i>Science</i> , 2019, 366, 1143-1149.	6.0	217
13	Hepatic Venous Occlusive Disease after Hematopoietic Stem Cell Transplantation: Risk Factors and Stratification, Prophylaxis, and Treatment. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 400-409.	2.0	213
14	Three prophylaxis regimens (tacrolimus, mycophenolate mofetil, and cyclophosphamide; tacrolimus,) Tj ETQq0 0 0 rgBT /Overlock 10 Tf methotrexate for prevention of graft-versus-host disease with haemopoietic cell transplantation with reduced-intensity conditioning: a randomised phase 2 trial with a non-randomised contemporaneous control group (BMT CTN 1203). <i>Lancet Haematology</i> , the, 2019, 6, e132-e143.	2.2	200
15	Autologous Transplantation, Consolidation, and Maintenance Therapy in Multiple Myeloma: Results of the BMT CTN 0702 Trial. <i>Journal of Clinical Oncology</i> , 2019, 37, 589-597.	0.8	184
16	Peripheral Blood Progenitor Cell Mobilization for Autologous and Allogeneic Hematopoietic Cell Transplantation: Guidelines from the American Society for Blood and Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1262-1273.	2.0	176
17	Hematopoietic recovery in patients receiving chimeric antigen receptor T-cell therapy for hematologic malignancies. <i>Blood Advances</i> , 2020, 4, 3776-3787.	2.5	162
18	Off-the-shelf EBV-specific T cell immunotherapy for rituximab-refractory EBV-associated lymphoma following transplantation. <i>Journal of Clinical Investigation</i> , 2020, 130, 733-747.	3.9	161

#	ARTICLE	IF	CITATIONS
19	T-cell Exhaustion in Multiple Myeloma Relapse after Autotransplant: Optimal Timing of Immunotherapy. <i>Cancer Immunology Research</i> , 2016, 4, 61-71.	1.6	152
20	American Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network, and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic Cell Transplantation in Patients with Relapsed Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 2039-2051.	2.0	146
21	IL-12-secreting CD19-targeted cord blood-derived T cells for the immunotherapy of B-cell acute lymphoblastic leukemia. <i>Leukemia</i> , 2015, 29, 415-422.	3.3	128
22	CC-486 Maintenance after Stem Cell Transplantation in Patients with Acute Myeloid Leukemia or Myelodysplastic Syndromes. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 2017-2024.	2.0	122
23	A phase 3 randomized study of 5-azacitidine maintenance vs observation after transplant in high-risk AML and MDS patients. <i>Blood Advances</i> , 2020, 4, 5580-5588.	2.5	122
24	Influence of infused cell dose and HLA match on engraftment after double-unit cord blood allografts. <i>Blood</i> , 2011, 117, 3277-3285.	0.6	121
25	Gut microbiome correlates of response and toxicity following anti-CD19 CAR T cell therapy. <i>Nature Medicine</i> , 2022, 28, 713-723.	15.2	117
26	High day 28 ST2 levels predict for acute graft-versus-host disease and transplant-related mortality after cord blood transplantation. <i>Blood</i> , 2015, 125, 199-205.	0.6	109
27	CAR-T "and a side order of IgG, to go?" Immunoglobulin replacement in patients receiving CAR-T cell therapy. <i>Blood Reviews</i> , 2019, 38, 100596.	2.8	109
28	Comparing CAR T-cell toxicity grading systems: application of the ASTCT grading system and implications for management. <i>Blood Advances</i> , 2020, 4, 676-686.	2.5	101
29	Favorable outcomes of COVID-19 in recipients of hematopoietic cell transplantation. <i>Journal of Clinical Investigation</i> , 2020, 130, 6656-6667.	3.9	101
30	The microbe-derived short-chain fatty acids butyrate and propionate are associated with protection from chronic GVHD. <i>Blood</i> , 2020, 136, 130-136.	0.6	97
31	Graft-versus-leukaemia effect after non-myeloablative haematopoietic transplantation can overcome the unfavourable expression of ZAP-70 in refractory chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2007, 137, 355-363.	1.2	95
32	Ex Vivo T Cell "Depleted versus Unmodified Allografts in Patients with Acute Myeloid Leukemia in First Complete Remission. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 898-903.	2.0	95
33	Gut Microbiota Predict Pulmonary Infiltrates after Allogeneic Hematopoietic Cell Transplantation. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2016, 194, 450-463.	2.5	95
34	Development and Evaluation of a Human Single Chain Variable Fragment (scFv) Derived Bcma Targeted CAR T Cell Vector Leads to a High Objective Response Rate in Patients with Advanced MM. <i>Blood</i> , 2017, 130, 742-742.	0.6	92
35	PR1 peptide vaccine induces specific immunity with clinical responses in myeloid malignancies. <i>Leukemia</i> , 2017, 31, 697-704.	3.3	90
36	Lenalidomide Maintenance for High-Risk Multiple Myeloma after Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1183-1189.	2.0	89

#	ARTICLE	IF	CITATIONS
37	Protective Factors in the Intestinal Microbiome Against Clostridium difficile Infection in Recipients of Allogeneic Hematopoietic Stem Cell Transplantation. <i>Journal of Infectious Diseases</i> , 2017, 215, 1117-1123.	1.9	81
38	Randomized Phase III BMT CTN Trial of Calcineurin Inhibitor-Free Chronic Graft-Versus-Host Disease Interventions in Myeloablative Hematopoietic Cell Transplantation for Hematologic Malignancies. <i>Journal of Clinical Oncology</i> , 2022, 40, 356-368.	0.8	79
39	Randomized, Double-Blind, Placebo-Controlled Trial of Soluble Tumor Necrosis Factor Receptor: Enbrel (Etanercept) for the Treatment of Idiopathic Pneumonia Syndrome after Allogeneic Stem Cell Transplantation: Blood and Marrow Transplant Clinical Trials Network Protocol. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 858-864.	2.0	78
40	Dominant unit CD34+ cell dose predicts engraftment after double-unit cord blood transplantation and is influenced by bank practice. <i>Blood</i> , 2014, 124, 2905-2912.	0.6	74
41	Compositional Flux Within the Intestinal Microbiota and Risk for Bloodstream Infection With Gram-negative Bacteria. <i>Clinical Infectious Diseases</i> , 2021, 73, e4627-e4635.	2.9	74
42	A phase 2 single-center study of carfilzomib 56 mg/m <sup>2</sup> with or without low-dose dexamethasone in relapsed multiple myeloma. <i>Blood</i> , 2014, 124, 899-906.	0.6	73
43	Clinical Responses and Pharmacokinetics of MCarH171, a Human-Derived Bcma Targeted CAR T Cell Therapy in Relapsed/Refractory Multiple Myeloma: Final Results of a Phase I Clinical Trial. <i>Blood</i> , 2018, 132, 959-959.	0.6	71
44	International harmonization in performing and reporting minimal residual disease assessment in multiple myeloma trials. <i>Leukemia</i> , 2021, 35, 18-30.	3.3	69
45	A Novel Reduced-Intensity Conditioning Regimen Induces a High Incidence of Sustained Donor-Derived Neutrophil and Platelet Engraftment after Double-Unit Cord Blood Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 799-803.	2.0	63
46	Safety and efficacy of talacotuzumab plus decitabine or decitabine alone in patients with acute myeloid leukemia not eligible for chemotherapy: results from a multicenter, randomized, phase 2/3 study. <i>Leukemia</i> , 2021, 35, 62-74.	3.3	63
47	Safety and Effectiveness of Weekly Carfilzomib, Lenalidomide, Dexamethasone, and Daratumumab Combination Therapy for Patients With Newly Diagnosed Multiple Myeloma. <i>JAMA Oncology</i> , 2021, 7, 862.	3.4	63
48	Long-term follow-up of BMT CTN 0702 (STaMINA) of postautologous hematopoietic cell transplantation (autoHCT) strategies in the upfront treatment of multiple myeloma (MM).. <i>Journal of Clinical Oncology</i> , 2020, 38, 8506-8506.	0.8	63
49	Letermovir for primary and secondary cytomegalovirus prevention in allogeneic hematopoietic cell transplant recipients: Real-world experience. <i>Transplant Infectious Disease</i> , 2019, 21, e13187.	0.7	62
50	Building a CAR Garage: Preparing for the Delivery of Commercial CAR T Cell Products at Memorial Sloan Kettering Cancer Center. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1135-1141.	2.0	60
51	Impact of TP53 Genomic Alterations in Large B-Cell Lymphoma Treated With CD19-Chimeric Antigen Receptor T-Cell Therapy. <i>Journal of Clinical Oncology</i> , 2022, 40, 369-381.	0.8	60
52	CD19 CAR T cells following autologous transplantation in poor-risk relapsed and refractory B-cell non-Hodgkin lymphoma. <i>Blood</i> , 2019, 134, 626-635.	0.6	59
53	Modified EASIX predicts severe cytokine release syndrome and neurotoxicity after chimeric antigen receptor T cells. <i>Blood Advances</i> , 2021, 5, 3397-3406.	2.5	59
54	Results of a Phase III Randomized, Multi-Center Study of Allogeneic Stem Cell Transplantation after High Versus Reduced Intensity Conditioning in Patients with Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML): Blood and Marrow Transplant Clinical Trials Network (BMT CTN) 0901. <i>Blood</i> , 2015, 126, LBA-8-LBA-8.	0.6	59

#	ARTICLE	IF	CITATIONS
55	Gain of chromosome 1q portends worse prognosis in multiple myeloma despite novel agent-based induction regimens and autologous transplantation. <i>Leukemia and Lymphoma</i> , 2017, 58, 1823-1831.	0.6	57
56	Racial disparities in access to HLA-matched unrelated donor transplants: a prospective 1312-patient analysis. <i>Blood Advances</i> , 2019, 3, 939-944.	2.5	56
57	Allogeneic stem cell transplantation for chronic lymphocytic leukemia in the era of novel agents. <i>Blood Advances</i> , 2020, 4, 3977-3989.	2.5	55
58	Early recovery of T-cell function predicts improved survival after T-cell depleted allogeneic transplant. <i>Leukemia and Lymphoma</i> , 2017, 58, 1859-1871.	0.6	54
59	Favorable Outcomes in Elderly Patients Undergoing High-Dose Therapy and Autologous Stem Cell Transplantation for Non-Hodgkin Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 2004-2009.	2.0	52
60	Early experience using salvage radiotherapy for relapsed/refractory non-Hodgkin lymphomas after CD19 chimeric antigen receptor (CAR) cell therapy. <i>British Journal of Haematology</i> , 2020, 190, 45-51.	1.2	51
61	Dynamics of minimal residual disease in patients with multiple myeloma on continuous lenalidomide maintenance: a single-arm, single-centre, phase 2 trial. <i>Lancet Haematology</i> , 2021, 8, e422-e432.	2.2	50
62	CD34-Selected Hematopoietic Stem Cell Transplants Conditioned with Myeloablative Regimens and Antithymocyte Globulin for Advanced Myelodysplastic Syndrome: Limited Graft-versus-Host Disease without Increased Relapse. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 2106-2114.	2.0	49
63	Treatment of multiple myeloma with monoclonal antibodies and the dilemma of false positive M-spikes in peripheral blood. <i>Clinical Biochemistry</i> , 2018, 51, 66-71.	0.8	49
64	Impact of High-Molecular-Risk Mutations on Transplantation Outcomes in Patients with Myelofibrosis. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1142-1151.	2.0	48
65	Geriatric assessment in older alloHCT recipients: association of functional and cognitive impairment with outcomes. <i>Blood Advances</i> , 2020, 4, 2810-2820.	2.5	47
66	Blood and Marrow Transplant Clinical Trials Network Report on the Development of Novel Endpoints and Selection of Promising Approaches for Graft-versus-Host Disease Prevention Trials. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1274-1280.	2.0	46
67	Frequent Human Herpesvirus-6 Viremia But Low Incidence of Encephalitis in Double-Unit Cord Blood Recipients Transplanted Without Antithymocyte Globulin. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 787-793.	2.0	43
68	Prognostic Importance of Pretransplant Functional Capacity After Allogeneic Hematopoietic Cell Transplantation. <i>Oncologist</i> , 2015, 20, 1290-1297.	1.9	43
69	Fecal microbiota diversity disruption and clinical outcomes after auto-HCT: a multicenter observational study. <i>Blood</i> , 2021, 137, 1527-1537.	0.6	42
70	Long-term survival in patients with peripheral T-cell non-Hodgkin lymphomas after allogeneic hematopoietic stem cell transplant. <i>Leukemia and Lymphoma</i> , 2012, 53, 1124-1129.	0.6	41
71	Accelerated single cell seeding in relapsed multiple myeloma. <i>Nature Communications</i> , 2020, 11, 3617.	5.8	41
72	The future of autologous stem cell transplantation in myeloma. <i>Blood</i> , 2014, 124, 328-333.	0.6	40

#	ARTICLE	IF	CITATIONS
73	High Disease-Free Survival with Enhanced Protection against Relapse after Double-Unit Cord Blood Transplantation When Compared with T Cellâ€“Depleted Unrelated Donor Transplantation in Patients with Acute Leukemia and Chronic Myelogenous Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1985-1993.	2.0	40
74	A Single-Center, Open-Label Trial of Isavuconazole Prophylaxis against Invasive Fungal Infection in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1195-1202.	2.0	40
75	Impact of geriatric vulnerabilities on allogeneic hematopoietic cell transplantation outcomes in older patients with hematologic malignancies. <i>Bone Marrow Transplantation</i> , 2020, 55, 157-164.	1.3	39
76	Robust CD4+ T-cell recovery in adults transplanted with cord blood and no antithymocyte globulin. <i>Blood Advances</i> , 2020, 4, 191-202.	2.5	36
77	A Phase II Study of a Nonmyeloablative Allogeneic Stem Cell Transplant with Peritransplant Rituximab in Patients with B-Cell Lymphoid Malignancies: Favorably Durable Event-Free Survival in Chemosensitive Patients. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 354-360.	2.0	35
78	Ex Vivo CD34+â€“Selected T Cellâ€“Depleted Peripheral Blood Stem Cell Grafts for Allogeneic Hematopoietic Stem Cell Transplantation in Acute Leukemia and Myelodysplastic Syndrome Is Associated with Low Incidence of Acute and Chronic Graft-versus-Host Disease and High Treatment Response. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 452-458.	2.0	35
79	Revaccination after Autologous Hematopoietic Stem Cell Transplantation Is Safe and Effective in Patients with Multiple Myeloma Receiving Lenalidomide Maintenance. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 871-876.	2.0	35
80	Weekly Carfilzomib, Lenalidomide, Dexamethasone and Daratumumab (wKRd-D) Combination Therapy Provides Unprecedented MRD Negativity Rates in Newly Diagnosed Multiple Myeloma: A Clinical and Correlative Phase 2 Study. <i>Blood</i> , 2019, 134, 862-862.	0.6	34
81	Intensified Mycophenolate Mofetil Dosing and Higher Mycophenolic Acid Trough Levels Reduce Severe Acute Graft-versus-Host Disease after Double-Unit Cord Blood Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 920-925.	2.0	33
82	Safety and Efficacy of Intermittent Intravenous Administration of High-Dose Micafungin. <i>Clinical Infectious Diseases</i> , 2015, 61, S652-S661.	2.9	32
83	Co-Infections by Double-Stranded DNA Viruses after Ex Vivo T Cellâ€“Depleted, CD34+ Selected Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1759-1766.	2.0	32
84	Impact of peri-transplant vancomycin and fluoroquinolone administration on rates of bacteremia in allogeneic hematopoietic stem cell transplant (HSCT) recipients: A 12-year single institution study. <i>Journal of Infection</i> , 2014, 69, 341-351.	1.7	31
85	Robust Vaccine Responses in Adult and Pediatric Cord Blood Transplantation Recipients Treated for Hematologic Malignancies. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 2160-2166.	2.0	31
86	Prospective Evaluation of Unrelated Donor Cord Blood and Haploidentical Donor Access Reveals Graft Availability Varies by Patient Ancestry: Practical Implications for Donor Selection. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 965-970.	2.0	31
87	Second Autologous Stem Cell Transplant: An Effective Therapy for Relapsed Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 468-472.	2.0	29
88	Cytomegalovirus Infection after CD34+ Selected Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1480-1486.	2.0	29
89	High progression-free survival after intermediate intensity double unit cord blood transplantation in adults. <i>Blood Advances</i> , 2020, 4, 6064-6076.	2.5	29
90	Maintenance with 5-Azacytidine for Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients. <i>Blood</i> , 2018, 132, 971-971.	0.6	29

#	ARTICLE	IF	CITATIONS
91	Relationship of BK Polyoma Virus (BKV) in the Urine with Hemorrhagic Cystitis and Renal Function in Recipients of TÁCellâ€Depleted Peripheral Blood and Cord Blood Stem Cell Transplantations. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1204-1210.	2.0	28
92	Germ cell tumors and associated hematologic malignancies evolve from a common shared precursor. <i>Journal of Clinical Investigation</i> , 2020, 130, 6668-6676.	3.9	28
93	Acupuncture for reduction of symptom burden in multiple myeloma patients undergoing autologous hematopoietic stem cell transplantation: a randomized sham-controlled trial. <i>Supportive Care in Cancer</i> , 2018, 26, 657-665.	1.0	27
94	Impact of Preemptive Therapy for Cytomegalovirus on Toxicities after Allogeneic Hematopoietic Cell Transplantation in Clinical Practice: A Retrospective Single-Center Cohort Study. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1482-1491.	2.0	27
95	Phase II Study of Infusional Carfilzomib in Patients with Relapsed or Refractory Multiple Myeloma. <i>Blood</i> , 2012, 120, 947-947.	0.6	27
96	Adenovirus Viremia in Adult CD34+ Selected Hematopoietic Cell Transplant Recipients: Low Incidence and High Clinical Impact. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 174-178.	2.0	26
97	Safety and feasibility of chimeric antigen receptor T cell therapy after allogeneic hematopoietic cell transplantation in relapsed/ refractory B cell non-Hodgkin lymphoma. <i>Leukemia</i> , 2019, 33, 2540-2544.	3.3	26
98	Development and validation of a disease risk stratification system for patients with haematological malignancies: a retrospective cohort study of the European Society for Blood and Marrow Transplantation registry. <i>Lancet Haematology</i> , the, 2021, 8, e205-e215.	2.2	26
99	Letermovir for Prevention of Cytomegalovirus Reactivation in Haploidentical and Mismatched Adult Donor Allogeneic Hematopoietic Cell Transplantation with Post-Transplantation Cyclophosphamide for Graft-versus-Host Disease Prophylaxis. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 85.e1-85.e6.	0.6	25
100	Early intestinal microbial features are associated with CD4 T-cell recovery after allogeneic hematopoietic transplant. <i>Blood</i> , 2022, 139, 2758-2769.	0.6	25
101	Hematopoietic Cell Transplantation Comorbidity Index Predicts Outcomes in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndromes Receiving CD34 + Selected Grafts for Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 67-74.	2.0	24
102	The International Prognostic Index Is Associated with Outcomes in Diffuse Large B Cell Lymphoma after Chimeric Antigen Receptor T Cell Therapy. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 233-240.	0.6	24
103	BRAF V600E Mutation and Clonal Evolution in a Patient With Relapsed Refractory Myeloma With Plasmablastic Differentiation. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2014, 14, e65-e68.	0.2	22
104	Allogeneic Hematopoietic Stem Cell Transplantation Is Underutilized in Older Patients with Myelodysplastic Syndromes. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1078-1086.	2.0	22
105	Toxicities of high-dose chemotherapy and autologous hematopoietic cell transplantation in older patients with lymphoma. <i>Blood Advances</i> , 2021, 5, 2608-2618.	2.5	22
106	Sustained Donor Engraftment in Recipients of Double-Unit Cord Blood Transplantation Is Possible Despite Donor-Specific Human Leukoctye Antigen Antibodies. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 735-739.	2.0	21
107	CD34-Selected Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Relapsed, High-Risk Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 258-267.	2.0	21
108	A Comprehensive Assessment of Toxicities in Patients with Central Nervous System Lymphoma Undergoing Autologous Stem Cell Transplantation Using Thiotepa, Busulfan, and Cyclophosphamide Conditioning. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 38-43.	2.0	21

#	ARTICLE	IF	CITATIONS
109	Allogeneic Stem Cell Transplantation for Advanced Myelodysplastic Syndrome: Comparison of Outcomes between CD34+ Selected and Unmodified Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1079-1087.	2.0	20
110	Impact of Letermovir Primary Cytomegalovirus Prophylaxis on 1-Year Mortality After Allogeneic Hematopoietic Cell Transplantation: A Retrospective Cohort Study. <i>Clinical Infectious Diseases</i> , 2022, 75, 795-804.	2.9	20
111	Phase 1/2 Trial of Carfilzomib Plus High-Dose Melphalan Preparative Regimen for Salvage Autologous Hematopoietic Cell Transplantation Followed by Maintenance Carfilzomib in Patients with Relapsed/Refractory Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1379-1385.	2.0	19
112	CD34+ Cell Selection versus Reduced-Intensity Conditioning and Unmodified Grafts for Allogeneic Hematopoietic Cell Transplantation in Patients Age >50 Years with Acute Myelogenous Leukemia and Myelodysplastic Syndrome. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 964-972.	2.0	19
113	Ex Vivo T Cell-Depleted Hematopoietic Stem Cell Transplantation for Adult Patients with Acute Myelogenous Leukemia in First and Second Remission: Long-Term Disease-Free Survival with a Significantly Reduced Risk of Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> . 2020. 26. 323-332.	2.0	19
114	Mass-Fix better predicts for PFS and OS than standard methods among multiple myeloma patients participating on the STAMINA trial (BMT CTN 0702 /07LT). <i>Blood Cancer Journal</i> , 2022, 12, 27.	2.8	19
115	MAIT and VÎ2 unconventional T cells are supported by a diverse intestinal microbiome and correlate with favorable patient outcome after allogeneic HCT. <i>Science Translational Medicine</i> , 2022, 14, .	5.8	19
116	â€œNo Washâ€•Albumin-Dextran Dilution for Double-Unit Cord Blood Transplantation is Safe with High Rates of Sustained Donor Engraftment. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 490-494.	2.0	18
117	Value-Based Care in Hematopoietic Cell Transplantation and Cellular Therapy: Challenges and Opportunities. <i>Current Hematologic Malignancy Reports</i> , 2018, 13, 125-134.	1.2	18
118	Auto-SCT improves survival in systemic light chain amyloidosis: a retrospective analysis with 14-year follow-up. <i>Bone Marrow Transplantation</i> , 2014, 49, 1036-1041.	1.3	17
119	Ex vivo and in vivo T cell-depleted allogeneic stem cell transplantation in patients with acute myeloid leukemia in first complete remission resulted in similar overall survival: on behalf of the ALWP of the EBMT and the MSKCC. <i>Journal of Hematology and Oncology</i> , 2018, 11, 127.	6.9	17
120	Phase I Study of Selinexor, Ixazomib, and Low-dose Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, 198-200.	0.2	17
121	Getting blood out of a stone: Identification and management of patients with poor hematopoietic cell mobilization. <i>Blood Reviews</i> , 2021, 47, 100771.	2.8	17
122	Venetoclax-based combinations in AML and high-risk MDS prior to and following allogeneic hematopoietic cell transplant. <i>Leukemia and Lymphoma</i> , 2021, 62, 3394-3401.	0.6	17
123	The Simplified Comorbidity Index: a new tool for prediction of nonrelapse mortality in allo-HCT. <i>Blood Advances</i> , 2022, 6, 1525-1535.	2.5	17
124	Relapse after Allogeneic Stem Cell Transplantation of Acute Myelogenous Leukemia and Myelodysplastic Syndrome and the Importance of Second Cellular Therapy. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 771.e1-771.e10.	0.6	17
125	Long term renal survival in patients undergoing T-Cell depleted versus conventional hematopoietic stem cell transplants. <i>Bone Marrow Transplantation</i> , 2017, 52, 733-738.	1.3	16
126	Allogeneic Hematopoietic Stem Cell Transplantation with Myeloablative Conditioning Is Associated with Favorable Outcomes in Mixed Phenotype Acute Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1879-1886.	2.0	16



#	ARTICLE	IF	CITATIONS
127	Myeloma in Elderly Patients: When Less Is More and More Is More. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2017, 37, 575-585.	1.8	16
128	Predictive biomarkers and practical considerations in the management of carfilzomib-associated cardiotoxicity. Leukemia and Lymphoma, 2018, 59, 1981-1985.	0.6	16
129	Impact of Toxicity on Survival for Older Adult Patients after CD34+ Selected Allogeneic Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2018, 24, 142-149.	2.0	16
130	The clinical implications of clonal hematopoiesis in hematopoietic cell transplantation. Blood Reviews, 2021, 46, 100744.	2.8	16
131	Reduced-intensity conditioning hematopoietic stem cell transplantation for chronic lymphocytic leukemia and Richter's transformation. Blood Advances, 2021, 5, 2879-2889.	2.5	16
132	Non-myeloablative allogeneic hematopoietic stem cell transplantation for adults with relapsed and refractory mantle cell lymphoma: a single-center analysis in the rituximab era. Bone Marrow Transplantation, 2015, 50, 1293-1298.	1.3	15
133	Higher Stem Cell Dose Infusion after Intensive Chemotherapy Does Not Improve Symptom Burden in Older Patients with Multiple Myeloma and Amyloidosis. Biology of Blood and Marrow Transplantation, 2016, 22, 226-231.	2.0	15
134	Validation of an Algorithm to Predict the Likelihood of an 8/8 HLA-Matched Unrelated Donor at Search Initiation. Biology of Blood and Marrow Transplantation, 2018, 24, 1057-1062.	2.0	15
135	Unlocking the Complex Flavors of Dysgeusia after Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2018, 24, 425-432.	2.0	15
136	Standard Antithymocyte Globulin Dosing Results in Poorer Outcomes in Overexposed Patients after Ex Vivo CD34+ Selected Allogeneic Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2019, 25, 1526-1535.	2.0	15
137	Significant Nationwide Variability in the Costs and Hospital Mortality Rates of Autologous Stem Cell Transplantation for Multiple Myeloma: An Analysis of the Nationwide Inpatient Sample Database. Biology of Blood and Marrow Transplantation, 2019, 25, 41-46.	2.0	15
138	Loss of plasmacytoid dendritic cell differentiation is highly predictive for post-induction measurable residual disease and inferior outcomes in acute myeloid leukemia. Haematologica, 2019, 104, 1378-1387.	1.7	15
139	Reduction of Opioid Use by Acupuncture in Patients Undergoing Hematopoietic Stem Cell Transplantation: Secondary Analysis of a Randomized, Sham-Controlled Trial. Pain Medicine, 2020, 21, 636-642.	0.9	14
140	Incidence and Risk Factors for Acute and Chronic Kidney Injury after Adult Cord Blood Transplantation. Biology of Blood and Marrow Transplantation, 2020, 26, 758-763.	2.0	14
141	Phase IB study of cabozantinib in patients with relapsed and/or refractory multiple myeloma. Blood, 2016, 127, 2355-2356.	0.6	13
142	Early Fluid Overload Is Associated with an Increased Risk of Nonrelapse Mortality after Ex Vivo CD34-Selected Allogeneic Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2018, 24, 2517-2522.	2.0	13
143	Strategies to improve outcomes of autologous hematopoietic cell transplant in lymphoma. Bone Marrow Transplantation, 2019, 54, 943-960.	1.3	13
144	The potential benefit of allogeneic over autologous transplantation in patients with very early relapsed and refractory follicular lymphoma with prior remission duration of $\geq 12$ months. British Journal of Haematology, 2016, 173, 260-264.	1.2	12

#	ARTICLE	IF	CITATIONS
145	Long-term prognosis for 1-year relapse-free survivors of CD34+ cell-selected allogeneic hematopoietic stem cell transplantation: a landmark analysis. <i>Bone Marrow Transplantation</i> , 2017, 52, 1629-1636.	1.3	12
146	T Cell Depletion as an Alternative Approach for Patients 55 Years or Older Undergoing Allogeneic Stem Cell Transplantation as Curative Therapy for Hematologic Malignancies. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1685-1694.	2.0	12
147	Antithymocyte globulin exposure in CD34+ T-cell-depleted allogeneic hematopoietic cell transplantation. <i>Blood Advances</i> , 2022, 6, 1054-1063.	2.5	12
148	Racial disparities in access to alternative donor allografts persist in the era of donors for all. <i>Blood Advances</i> , 2022, 6, 5625-5629.	2.5	12
149	The Impact of Toxicities on First-Year Outcomes after Ex Vivo CD34+ Selected Allogeneic Hematopoietic Cell Transplantation in Adults with Hematologic Malignancies. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 2004-2011.	2.0	11
150	Upfront use of plerixafor and granulocyte-colony stimulating factor (G-CSF) for stem cell mobilization in patients with multiple myeloma: efficacy and analysis of risk factors associated with poor stem cell collection efficiency*. <i>Leukemia and Lymphoma</i> , 2017, 58, 1123-1129.	0.6	11
151	Cytomegalovirus resistance in CD34+ selected hematopoietic cell transplant recipients. <i>Transplant Infectious Disease</i> , 2018, 20, e12881.	0.7	11
152	Effects of Late Toxicities on Outcomes in Long-Term Survivors of Ex-Vivo CD34+-Selected Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 133-141.	2.0	11
153	Impact of Preemptive Therapy for Cytomegalovirus on Hospitalizations and Cost after Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1937-1947.	2.0	11
154	Cellular Therapy During COVID-19: Lessons Learned and Preparing for Subsequent Waves. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 438.e1-438.e6.	0.6	11
155	Prognostic Score and Cytogenetic Risk Classification for Chronic Lymphocytic Leukemia Patients: Center for International Blood and Marrow Transplant Research Report. <i>Clinical Cancer Research</i> , 2019, 25, 5143-5155.	3.2	10
156	Pilot Study of Bortezomib and Dexamethasone Pre- and Post-Risk-Adapted Autologous Stem Cell Transplantation in AL Amyloidosis. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 204-208.	2.0	10
157	Pilot Study of Telehealth Evaluations in Patients Undergoing Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, e135-e137.	2.0	10
158	Tailored treatment to MRD response: A phase I/II study for newly diagnosed multiple myeloma patients using high dose twice-weekly carfilzomib (45 and 56 mg/m <sup>2</sup> ) in combination with lenalidomide and dexamethasone. <i>American Journal of Hematology</i> , 2021, 96, E193-E196.	2.0	10
159	Association between Nondominant Unit Total Nucleated Cell Dose and Engraftment in Myeloablative Double-Unit Cord Blood Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1981-1984.	2.0	9
160	Severe pembrolizumab-associated neutropenia after CD34+ selected allogeneic hematopoietic-cell transplantation for multiple myeloma. <i>Bone Marrow Transplantation</i> , 2018, 53, 1065-1068.	1.3	9
161	Distinctive Infectious Complications in Patients with Central Nervous System Lymphoma Undergoing Thiotepa, Busulfan, and Cyclophosphamide-conditioned Autologous Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1914-1919.	2.0	9
162	Measurement of the DNA alkylating agents busulfan and melphalan in human plasma by mass spectrometry. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2019, 1125, 121711.	1.2	9

#	ARTICLE	IF	CITATIONS
163	Lack of a significant pharmacokinetic interaction between letermovir and calcineurin inhibitors in allogeneic HCT recipients. <i>Bone Marrow Transplantation</i> , 2020, 55, 1687-1689.	1.3	9
164	Prospective KIR genotype evaluation of hematopoietic cell donors is feasible with potential to benefit patients with AML. <i>Blood Advances</i> , 2021, 5, 2003-2011.	2.5	9
165	Loss of Microbiota Diversity after Autologous Stem Cell Transplant Is Comparable to Injury in Allogeneic Stem Cell Transplant. <i>Blood</i> , 2018, 132, 608-608.	0.6	9
166	Second Allogeneic Stem Cell Transplantation for Acute Leukemia Using a Chemotherapy-Only Cyto-reduction with Clofarabine, Melphalan, and Thiotepa. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1449-1454.	2.0	8
167	End-of-life care for older AML patients relapsing after allogeneic stem cell transplant at a dedicated cancer center. <i>Bone Marrow Transplantation</i> , 2019, 54, 700-706.	1.3	8
168	Presalvage International Staging System Stage and Other Important Outcome Associations in CD34+-Selected Allogeneic Hematopoietic Stem Cell Transplantation for Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 58-65.	2.0	8
169	Engraftment kinetics after transplantation of double unit cord blood grafts combined with haplo-identical CD34+ cells without antithymocyte globulin. <i>Leukemia</i> , 2021, 35, 850-862.	3.3	8
170	Stem Cell Mobilization and Autograft Minimal Residual Disease Negativity with Novel Induction Regimens in Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1394-1401.	2.0	8
171	Biomarkers of Cardiotoxicity Among Multiple Myeloma Patients Subsequently Treated with Proteasome Inhibitor Therapy. <i>Blood</i> , 2015, 126, 4257-4257.	0.6	8
172	Allogeneic Hematopoietic Stem Cell Transplantation for Multiple Myeloma: What Place, If Any?. <i>Current Hematologic Malignancy Reports</i> , 2013, 8, 284-290.	1.2	7
173	Identifying Professional Education Gaps and Barriers in Multiple Myeloma Patient Care: Findings of the Managing Myeloma Continuing Educational Initiative Advisory Committee. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2014, 14, 356-369.	0.2	7
174	Proteomic profiling in plasma cell disorders: a feasibility study. <i>Leukemia and Lymphoma</i> , 2017, 58, 1757-1759.	0.6	7
175	Cytomegalovirus Infection in Allogeneic Hematopoietic Cell Transplantation Managed by the Preemptive Approach: Estimating the Impact on Healthcare Resource Utilization and Outcomes. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 791-799.	2.0	7
176	Immune Cytopenias after Ex Vivo CD34+-Selected Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1136-1141.	2.0	7
177	Adenovirus Viral Kinetics and Mortality in Ex Vivo T Cell-Depleted Hematopoietic Cell Transplant Recipients With Adenovirus Infection From a Single Center. <i>Journal of Infectious Diseases</i> , 2020, 222, 1180-1187.	1.9	7
178	Universal Engraftment after Allogeneic Hematopoietic Cell Transplantation Using Cryopreserved CD34-Selected Grafts. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 697.e1-697.e5.	0.6	7
179	Double-Unit Cord Blood (CB) Transplantation Combined With Haplo-Identical CD34+ Cell-Selected PBSC Results In 100% CB Engraftment With Enhanced Myeloid Recovery. <i>Blood</i> , 2013, 122, 298-298.	0.6	7
180	Polyclonal IgA Gammopathy Associated with Polyclonal Plasmacytosis in Patients Receiving Lenalidomide Maintenance Therapy. <i>Blood</i> , 2011, 118, 5130-5130.	0.6	7

#	ARTICLE	IF	CITATIONS
181	Myeloproliferative Neoplasm Quality Of Life (MPN-QOL) Study Group: Observational Study Of Quality Of Life and Symptomatic Response In Myelofibrosis Patients Receiving Undergoing Treatment With Conventional Therapy, The Measures Trial and Allogeneic Stem Cell Transplant, The Symptoms Trial. <i>Blood</i> , 2013, 122, 4090-4090.	0.6	7
182	Nutrition perceptions, needs and practices among patients with plasma cell disorders. <i>Blood Cancer Journal</i> , 2022, 12, 70.	2.8	7
183	Low incidence of GvHD with T-cell depleted allografts facilitates further treatments for post-transplantation relapse in AML and MDS. <i>Bone Marrow Transplantation</i> , 2016, 51, 991-993.	1.3	6
184	Utility of Bronchoscopy with Bronchoalveolar Lavage among Hematologic Transplant Recipients in the Era of Noninvasive Testing. <i>Respiration</i> , 2021, 100, 339-346.	1.2	6
185	Adoptive T-Cell Therapy with 3rd Party CMV-pp65-Specific CTLs for CMV Viremia and Disease Arising after Allogeneic Hematopoietic Stem Cell Transplant. <i>Blood</i> , 2017, 130, 747-747.	0.6	6
186	Phase I/II Trial of Paclitaxel With Ifosfamide Followed by High-Dose Paclitaxel, Ifosfamide, and Carboplatin (TI-TIC) With Autologous Stem Cell Reinfusion for Salvage Treatment of Germ Cell Tumors. <i>Clinical Genitourinary Cancer</i> , 2015, 13, 453-460.	0.9	5
187	Utility of a patient-reported outcome in measuring functional impairment during autologous stem cell transplant in patients with multiple myeloma. <i>Quality of Life Research</i> , 2018, 27, 979-985.	1.5	5
188	First Description of B Cell Maturation Antigen Expression in Light Chain Amyloidosis. <i>Blood</i> , 2019, 134, 5452-5452.	0.6	5
189	Poor Graft Function in Recipients of T Cell Depleted (TCD) Allogeneic Hematopoietic Stem Cell Transplants (HSCT) Is Mostly Related to Viral Infections and Anti-Viral Therapy. <i>Blood</i> , 2012, 120, 3147-3147.	0.6	5
190	Hematopoietic Cell Transplantation is Feasible in Patients with Prior COVID-19 Infection. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 55.e1-55.e5.	0.6	5
191	Antibiotic Exposures and Dietary Intakes Are Associated with Changes in Microbiota Compositions in Allogeneic Hematopoietic Stem Cell Transplant Patients. <i>Blood</i> , 2019, 134, 597-597.	0.6	5
192	Busulfan-based conditioning regimens: not all partners are equal. <i>Lancet Oncology</i> , The, 2015, 16, 1448-1449.	5.1	4
193	Immunophenotypic evidence for reactive polyclonal marrow plasmacytosis in multiple myeloma patients receiving lenalidomide maintenance. <i>Leukemia and Lymphoma</i> , 2017, 58, 2962-2965.	0.6	4
194	Novel agents may positively impact chemotherapy and transplantation in subsets of diffuse large B-cell lymphoma. <i>Expert Review of Hematology</i> , 2019, 12, 407-418.	1.0	4
195	Geriatric syndromes in 2-year, progression-free survivors among older recipients of allogeneic hematopoietic cell transplantation. <i>Bone Marrow Transplantation</i> , 2021, 56, 289-292.	1.3	4
196	The Prognostic Calculator Easix Predicts Acute Gvhd, Non-Relapse Mortality and Overall Survival in Adult Patients Undergoing Reduced Intensity Conditioning Allogeneic HCT. <i>Blood</i> , 2018, 132, 2069-2069.	0.6	4
197	Presence of PD-1 Expressing T Cells Predicts for Inferior Overall Survival in Newly Diagnosed Multiple Myeloma. <i>Blood</i> , 2015, 126, 1785-1785.	0.6	4
198	Successful Treatment of Peripheral T-Cell Lymphoma with Allogeneic Stem Cell Transplantation: A Large Single-Center Experience. <i>Blood</i> , 2015, 126, 4392-4392.	0.6	4

#	ARTICLE	IF	CITATIONS
199	Selection of Unrelated Allogeneic Hematopoietic Cell Donors Based on KIR3DL1 Allotypes Is Feasible and Results in Improved Disease-Free Survival in Transplant Recipients with MDS and AML. <i>Blood</i> , 2016, 128, 990-990.	0.6	4
200	Low-dose unfractionated heparin prophylaxis is a safe strategy for the prevention of hepatic sinusoidal obstruction syndrome after myeloablative adult allogeneic stem cell transplant. <i>Bone Marrow Transplantation</i> , 2022, 57, 1095-1100.	1.3	4
201	African American patients with smoldering multiple myeloma may have a lower risk of progression compared to White patients.. <i>Journal of Clinical Oncology</i> , 2022, 40, 8045-8045.	0.8	4
202	Double-Unit Cord Blood (CB) Transplantation Combined with Haplo-Identical CD34+ Cells Results in 100% CB Engraftment with Enhanced Myeloid Recovery. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, S138-S139.	2.0	3
203	Syngeneic hematopoietic stem cell transplantation from HTLV-1 seropositive twin for adult T-cell leukemia-lymphoma. <i>Bone Marrow Transplantation</i> , 2018, 53, 654-656.	1.3	3
204	Novel agents positively impact chemotherapy and transplantation in Hodgkin lymphoma. <i>Expert Review of Hematology</i> , 2019, 12, 255-264.	1.0	3
205	Compliments to complement blockade for TA-TMA. <i>Blood</i> , 2020, 135, 981-983.	0.6	3
206	CD34+ -selected hematopoietic stem cell transplant conditioned with a myeloablative regimen in patients with advanced myelofibrosis. <i>Bone Marrow Transplantation</i> , 2022, 57, 1101-1107.	1.3	3
207	Anatomy of a Successful Practice-Changing Study: A Blood and Marrow Transplantation Clinical Trials Network-National Cancer Institute Cooperative Group Collaboration. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 858-859.	2.0	2
208	Treatment of Transplant-Eligible Patients with Multiple Myeloma in 2014. <i>Hematology/Oncology Clinics of North America</i> , 2014, 28, 815-827.	0.9	2
209	BK polyoma virus nephropathy in hematopoietic cell transplant recipients. <i>Journal of Onco-Nephrology</i> , 2019, 3, 113-123.	0.3	2
210	Use of anti-thymocyte globulin (ATG) for the treatment of pure red cell aplasia and immune-mediated cytopenias after allogeneic hematopoietic cell transplantation: a case series. <i>Bone Marrow Transplantation</i> , 2020, 55, 2326-2330.	1.3	2
211	Outcomes of adult T-Cell leukemia/lymphoma with allogeneic stem cell transplantation: single-institution experience. <i>Leukemia and Lymphoma</i> , 2021, 62, 2177-2183.	0.6	2
212	Homebound Autologous Hematopoietic Cell Transplantation for Plasma Cell Disorders in an Urban Setting Is Safe for Patients and Preferred By Patients and Caregivers. <i>Blood</i> , 2018, 132, 2258-2258.	0.6	2
213	Risk-Adapted Melphalan and Stem Cell Transplant for Systemic Light Chain Amyloidosis: A Single Institution Experience.. <i>Blood</i> , 2012, 120, 3109-3109.	0.6	2
214	Prospective Evaluation Of Alternative Donor Availability In 708 Patients: Improved Allograft Access With Enlarging CB Inventory For All Patients Including Racial and Ethnic Minorities. <i>Blood</i> , 2013, 122, 162-162.	0.6	2
215	Multiple Copies of MLL Is The Most Commonly Detected Cytogenetic Abnormality In Newly Diagnosed Multiple Myeloma and May Modify Disease Risk. <i>Blood</i> , 2013, 122, 1910-1910.	0.6	2
216	Intensified Mycophenolate Mofetil (MMF) Dosing Every 8 Hours Is Safe From The Standpoint Of Engraftment and May Ameliorate Severe Acute Graft-Versus-Host Disease (GVHD) After Double-Unit Cord Blood Transplantation (CBT). <i>Blood</i> , 2013, 122, 4600-4600.	0.6	2

#	ARTICLE	IF	CITATIONS
217	Two Chemotherapy-Based Conditioning Regimens Compared To TBI-Based Conditioning Secure Consistent Engraftment Of T-Cell Depleted Allogeneic HSCT, Similarly Low Incidences Of Gvhd and Favorable Rates Of Disease-Free Survival (DFS). Blood, 2013, 122, 546-546.	0.6	2
218	MAIT and V $\alpha$ 2 Unconventional T Cells Predict Favorable Outcome after Allogeneic HCT and Are Supported By a Diverse Intestinal Microbiome. Blood, 2021, 138, 331-331.	0.6	2
219	Association of Patient Activity Bioprofiles with Hrql and Clinical Responses: A Prospective Novel Trial Using Mobile Wearables in Newly Diagnosed Multiple Myeloma Patients. Blood, 2020, 136, 26-28.	0.6	2
220	Impact of omitting post-transplant minidose-methotrexate doses in allogeneic hematopoietic cell transplantation. Leukemia and Lymphoma, 2022, 63, 1686-1693.	0.6	2
221	Ionizing radiation exposure after allogeneic hematopoietic cell transplantation. Bone Marrow Transplantation, 2022, 57, 827-829.	1.3	2
222	Capture Rate of V(D)J Sequencing for Minimal Residual Disease Detection in Multiple Myeloma. Clinical Cancer Research, 2022, 28, 2160-2166.	3.2	2
223	Impact of a shared-care model between community and academic centers for facilitating access to allogeneic and autologous stem cell transplantation.. Journal of Clinical Oncology, 2022, 40, 1510-1510.	0.8	2
224	Defibrotide for the treatment of severe hepatic veno-occlusive disease/sinusoidal obstruction syndrome: evidence for clinical benefit. Expert Opinion on Orphan Drugs, 2015, 3, 1491-1501.	0.5	1
225	Hematopoietic stem cell transplantation. , 2016, , 440-451.		1
226	Case-based roundtable on treatment approach for young, fit, newly diagnosed multiple myeloma patients. Hematology American Society of Hematology Education Program, 2018, 2018, 103-109.	0.9	1
227	Prognostic Factors for Postrelapse Survival after ex Vivo CD34+-Selected (T Cell-Depleted) Allogeneic Hematopoietic Cell Transplantation in Multiple Myeloma. Biology of Blood and Marrow Transplantation, 2020, 26, 2040-2046.	2.0	1
228	A key step towards setting a benchmark for tackling transplant-associated thrombotic microangiopathy. British Journal of Haematology, 2020, 189, 1006-1009.	1.2	1
229	Characteristics and Impact of Post-Transplant Interdisciplinary Palliative Care Consultation in Older Allogeneic Hematopoietic Cell Transplant Recipients. Journal of Palliative Medicine, 2020, 23, 1653-1657.	0.6	1
230	A simplified <scp>CD34</scp>+ based preharvest prediction tool for <scp>HPC(A)</scp> collection. Transfusion, 2021, 61, 1525-1532.	0.8	1
231	Oral Proteasome Inhibitor Ixazomib for Switch-Maintenance Prophylaxis of Recurrent or Late Acute and Chronic Graft-versus-Host Disease after Day 100 in Allogeneic Stem Cell Transplantation. Transplantation and Cellular Therapy, 2021, 27, 920.e1-920.e9.	0.6	1
232	A Simple Geriatric Vulnerability Index for Older Patients Undergoing Allogeneic Hematopoietic Cell Transplantation. Blood, 2018, 132, 2176-2176.	0.6	1
233	Impact of Non High-Risk Chromosomal Abnormalities on the Outcome of Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma. Blood, 2011, 118, 333-333.	0.6	1
234	EBMT Risk Score for Pre Transplant Risk Assessment in Patients with Multiple Myeloma.. Blood, 2012, 120, 3094-3094.	0.6	1

#	ARTICLE	IF	CITATIONS
235	Cryotherapy Reduces Mucositis in Multiple Myeloma Patients Receiving High-Dose Melphalan Conditioning Prior to Autologous Stem Cell Transplantation. <i>Blood</i> , 2012, 120, 4265-4265.	0.6	1
236	Pilot Study To Evaluate The Prevalence Of Actionable Oncogenic Mutations In Patients With Relapsed Refractory Multiple Myeloma. <i>Blood</i> , 2013, 122, 755-755.	0.6	1
237	Upfront Plerixafor Plus G-CSF Versus Cyclophosphamide Plus G-CSF for Autologous Stem Cell Mobilization in Multiple Myeloma Patients: An Update on Cost Analysis Study at Memorial Sloan Kettering Cancer Center. <i>Blood</i> , 2014, 124, 848-848.	0.6	1
238	Induction with Bortezomib and Dexamethasone (BD) Followed By Risk Adapted High Dose Melphalan and Autologous Stem Cell Transplantation and BD Consolidation in Patients with AL Amyloidosis: A Phase II Feasibility Study. <i>Blood</i> , 2015, 126, 3178-3178.	0.6	1
239	Impact of Genomic Alterations on Outcomes in Myelofibrosis Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation. <i>Blood</i> , 2016, 128, 2301-2301.	0.6	1
240	Role of Serum Lactate Dehydrogenase (LDH) As a Prognostic Marker for Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma.. <i>Blood</i> , 2012, 120, 3115-3115.	0.6	1
241	Sequential Treatment After Allogeneic Stem Cell Transplantation for Chronic Myelogenous Leukemia.. <i>Blood</i> , 2012, 120, 3129-3129.	0.6	1
242	Analysis of 129 Myeloablative Double-Unit Cord Blood Transplantation Recipients Demonstrates an Independent Association Between Non-Dominant Unit TNC Dose and Engraftment Suggesting a Facilitation Effect. <i>Blood</i> , 2014, 124, 2459-2459.	0.6	1
243	A Pilot Plant-Based Dietary Intervention in Overweight and Obese Patients with Monoclonal Gammopathy of Undetermined Significance and Smoldering Multiple Myeloma- the Nutrition Prevention (NUTRIVENTION) Study. <i>Blood</i> , 2021, 138, 4759-4759.	0.6	1
244	Post-Transplant Inotuzumab Ozogamicin for Acute Lymphoblastic Leukemia. <i>Blood</i> , 2021, 138, 2899-2899.	0.6	1
245	Racial Disparities in Access to Alternative Donor Allografts Persist in the Era of "Donors for All". <i>Blood</i> , 2021, 138, 423-423.	0.6	1
246	Clinical Impact of Bridging Therapy Prior to Commercial Chimeric Antigen Receptor (CAR) T-Cell Therapies for Relapsed/Refractory Lymphomas. <i>Blood</i> , 2020, 136, 1-2.	0.6	1
247	VRd Versus KRd Safety Profiles in Newly Diagnosed Multiple Myeloma Patients Using Real-World Evidence Data from a Single Institution: VRd Has High Rates of Chronic Neuropathy, and KRd Has Low Rates of Cardiopulmonary or Renal Toxicities When Using Optimized IV Fluid Management Coupled with Baseline Cardiac Workup. <i>Blood</i> , 2020, 136, 37-38.	0.6	1
248	Weekly Carfilzomib, Lenalidomide, Dexamethasone and Daratumumab (wKRd-D) Combination Therapy in Newly Diagnosed Multiple Myeloma: Final Results from a Clinical and Correlative Phase 2 Study. <i>Blood</i> , 2020, 136, 7-7.	0.6	1
249	TCR Repertoires in Graft-Versus-Host-Disease (GVHD)-Target Tissues Reveals Tissue Specificity of the Alloimmune Response. <i>Blood</i> , 2020, 136, 21-23.	0.6	1
250	Continuous induction with lenalidomide/dexamethasone versus autologous stem cell transplantation in newly diagnosed multiple myeloma: a case for response-adapted approach. <i>Leukemia and Lymphoma</i> , 0, , 1-10.	0.6	1
251	Evaluating serum-free light chain ratio as a biomarker for multiple myeloma.. <i>Journal of Clinical Oncology</i> , 2022, 40, 8047-8047.	0.8	1
252	Favorable long-term outcomes of hematopoietic stem cell transplantation for CMML with myeloablative conditioning, anti-thymocyte globulin, and CD34+ selected graft. <i>Bone Marrow Transplantation</i> , 2020, 55, 1632-1634.	1.3	0

#	ARTICLE	IF	CITATIONS
253	Primary refractory multiple myeloma – what role for high dose melphalan?. <i>Leukemia and Lymphoma</i> , 2020, 61, 2785-2785.	0.6	0
254	A phase II clinical trial of lenalidomide intensification in patients with serologic/asymptomatic progression of multiple myeloma while on lenalidomide maintenance: a tri-state transplant consortium study. <i>Leukemia and Lymphoma</i> , 2020, 61, 488-490.	0.6	0
255	The post-transplant scoring system (PTSS) is associated with outcomes in patients with MDS after CD34+selected allogeneic stem cell transplant. <i>Bone Marrow Transplantation</i> , 2021, 56, 2749-2754.	1.3	0
256	Fractionated Infusion of Hematopoietic Progenitor Cells Does Not Improve Neutrophil Recovery or Survival in Allograft Recipients. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 852.e1-852.e9.	0.6	0
257	High Number of Successful Mobilizations Associated with the Use of Plerixafor and Colony Stimulating Factors In Patients with Multiple Myeloma (MM) and Lymphoma Treated at Memorial Sloan-Kettering Cancer Center. <i>Blood</i> , 2010, 116, 2263-2263.	0.6	0
258	Concordance Between the Serum Levels of Interleukin-6, MicroRNA-21, and the Severity of Subjective Symptoms of Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation. <i>Blood</i> , 2010, 116, 2953-2953.	0.6	0
259	Unrelated Donor T-Cell Depleted (TCD) Hematopoietic Stem Cell Transplantation (HSCT) for Patients with Advanced Myelodysplastic Syndromes (MDS): The MSKCC Experience. <i>Blood</i> , 2012, 120, 1996-1996.	0.6	0
260	Fractionated Stem Cell Infusions for Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplant. <i>Blood</i> , 2012, 120, 4550-4550.	0.6	0
261	Outcome of Stem Cell Transplantation in Adults with Acute Myelogenous Leukemia and Normal Cytogenetics (NC-AML) According to Presence of FLT-3 Internal Tandem Duplication (FLT-3ITD) At the Time of Diagnosis. <i>Blood</i> , 2012, 120, 2038-2038.	0.6	0
262	High Day 28 ST2 Biomarker Levels Predict Severe Day 100 Acute Graft-Versus-Host Disease and Day 180 Transplant-Related Mortality After Double-Unit Cord Blood Transplantation. <i>Blood</i> , 2013, 122, 146-146.	0.6	0
263	Multiparameter Flow Cytometry For Detection Of Minimal Residual Disease In Multiple Myeloma After T-Cell Depleted Allogeneic Stem Cell Transplant. <i>Blood</i> , 2013, 122, 4647-4647.	0.6	0
264	Efficacy and Risk Factors Analysis of Upfront Autologous Stem Cell Mobilization Using Plerixafor and Granulocyte-Colony Stimulating Factor (GCSF) in Patients with Multiple Myeloma. <i>Blood</i> , 2014, 124, 3856-3856.	0.6	0
265	Continuous Treatment with Lenalidomide Plus Low-Dose Dexamethasone (Ld) Versus Ld Induction Followed By Autologous Stem Cell Transplant (ASCT) in Patients with Newly Diagnosed Multiple Myeloma (NDMM): A Pooled Analysis of Two Randomized Clinical Trials. <i>Blood</i> , 2015, 126, 1975-1975.	0.6	0
266	Prognostic Factors of CLL Patients Undergoing Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantation in the Immunochemotherapy Era. <i>Blood</i> , 2016, 128, 5865-5865.	0.6	0
267	Whole Exome Sequencing from Nine Independent Sites of Extramedullary Disease in a Single Patient with Relapsed Multiple Myeloma Show That Extramedullary Disease Arise through a Combination of Branched and Parallel Evolution. <i>Blood</i> , 2016, 128, 2090-2090.	0.6	0
268	Burden and Impact of Geriatric Syndromes Associated with Allogeneic Hematopoietic Cell Transplantation in Older Adults. <i>Blood</i> , 2018, 132, 3370-3370.	0.6	0
269	Long-Term Sustained Minimal Residual Disease (MRD) Negativity in Patients with Multiple Myeloma Treated with Continuous Lenalidomide Maintenance Therapy: A Clinical and Correlative Phase 2 Study. <i>Blood</i> , 2020, 136, 18-19.	0.6	0
270	Clinical Outcomes of Acute Myeloid Leukemia Patients Bridged to Allogeneic Stem Cell Transplant By Venetoclax Combination Therapy. <i>Blood</i> , 2020, 136, 16-17.	0.6	0



#	ARTICLE	IF	CITATIONS
271	A Pilot Study Evaluating Lenalidomide and CC-486 in Combination with Radiotherapy for Patients with Plasmacytoma (LENAZART study). <i>Blood</i> , 2020, 136, 8-10.	0.6	0
272	Maintenance Use Is More Important Than the Choice of Bortezomib-Based Triplet Induction in Newly Diagnosed Multiple Myeloma Patients Undergoing Upfront Autologous Stem Cell Transplantation. <i>Blood</i> , 2020, 136, 36-37.	0.6	0
273	Secondary Graft-Versus-Host Disease (GVHD) Prophylaxis with Oral Proteasome Inhibitor Ixazomib Is Associated with Low Incidence of Recurrent, Late Acute and Chronic GVHD and Facilitated Calcineurin Inhibitor Taper within the First Year Post Allogeneic Stem Cell Transplantation. <i>Blood</i> , 2020, 136, 41-42.	0.6	0
274	Rabbit Anti-Thymocyte Globulin Exposure (rATG) in CD34+ Selected Hematopoietic Cell Transplantation and Its Impact on Immune Reconstitution and Outcomes in Children and Adults. <i>Blood</i> , 2020, 136, 30-31.	0.6	0
275	Evaluation of Melphalan Exposure in Lymphoma Patients Undergoing BEAM and Autologous Hematopoietic Cell Transplantation. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 485.e1-485.e6.	0.6	0
276	Disparities in speed to BMT consult and allograft in 279 adults with AML.. <i>Journal of Clinical Oncology</i> , 2022, 40, 6523-6523.	0.8	0
277	Clinical efficacy of daratumumab (DARA)-based second line therapy after DARA-containing and DARA-free induction therapies in multiple myeloma: A single center experience.. <i>Journal of Clinical Oncology</i> , 2022, 40, e20005-e20005.	0.8	0